Investment
Features
FeesSafety
Academy
More
Pluang+

Compare First Trust NASDAQ Clean Edge Green Energy Idx Fd (QCLN) vs Twist Bioscience Corp (TWST) Price & Performance

First Trust NASDAQ Clean Edge Green Energy Idx FdTrade
Twist Bioscience CorpTrade

Price performance (Past 24H)

Key statistics

First Trust NASDAQ Clean Edge Green Energy Idx Fd vs Twist Bioscience Corp — how do they compare? First Trust NASDAQ Clean Edge Green Energy Idx Fd trades at $49.35, while Twist Bioscience Corp trades at $125.52 (market cap $8.42B). The key difference: Twist Bioscience Corp is trading nearer its 52-week high, First Trust NASDAQ Clean Edge Green Energy Idx Fd nearer its low. Which is the better fit depends on your goals.

QCLNTWST
Sector
Sector/ThematicHealth
52-Week High
$68.47$153.10
52-Week Low
$37.69$24.16
Market Cap
$8.42B
Enterprise Value
$8.35B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

First Trust NASDAQ Clean Edge Green Energy Idx Fd

QCLN trades at $50.57, up 2.31% today, with a bullish technical signal overall despite bearish moving averages. The ETF is positioned to benefit from global renewable energy acceleration driven by geopolitical tensions and rising data center power demand. Recent news highlights its sensitivity to U.S. political outcomes and federal clean energy policy, with historical outperformance ahead of midterm elections.

The outlook is supported by structural tailwinds in clean energy adoption, but risks include regulatory uncertainty and permit delays under current U.S. administration. Investment appeal hinges on policy continuity and execution of global renewable projects, with volatility expected around political developments.

Twist Bioscience Corp

Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.

TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.

Returns comparison

Trailing returns across standard periods

About First Trust NASDAQ Clean Edge Green Energy Idx Fd

QCLN invests in U.S.-listed companies engaged in clean energy technologies. It focuses on solar power, wind, electric vehicles, and energy storage, with major holdings in firms like Tesla, ON Semiconductor, and Rivian.

Read more on QCLN

About Twist Bioscience Corp

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.

Read more on TWST